arrow
M

Michelle L. O'Donoghue

Harvard University
H指数:59
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics

HPS-4/TIMI 65/ORION-4:一项双盲、随机、安慰剂对照试验,评估依洛尤单抗对动脉粥样硬化性心血管疾病患者临床结局的影响:试验设计、招募和基线特征

2026-09-010
PRE
A polygenic risk score for peripheral artery disease and major adverse limb events

外周动脉疾病及主要肢体不良事件的polygenic risk score

2025-11-010
PRE
Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials

个体参与者数据meta分析中系统缺失协变量的统计方法:基于5项大型心血管试验的见解与应用

2025-11-010
OA
Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease

动脉粥样硬化疾病谱中冠状动脉疾病的多基因风险评分

2025-11-010
PRE
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension

克服开发与实施新型高血压疗法的障碍

2025-10-010
PRE
Fibrinolytic Therapy for Thromboembolic Diseases

血栓栓塞性疾病溶栓治疗

JACC
IF0
2025-09-290
PRE
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial

抗体介导的LOX-1抑制在心肌梗死后残留炎症患者中的疗效:一项随机第2期临床试验

2025-09-250
PRE
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk

一种用于预测全谱心血管风险范围内新发心力衰竭的多基因风险评分

JACC
IF0
2025-08-270
PRE
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers Results From the OCEAN(a)-DOSE Trial

Olpasiran、氧化磷脂和系统性炎症生物标志物结果:来自OCEAN(a)-DOSE试验

2025-02-122
PRE
Sex differences in treatment strategies for pulmonary embolism in older adults: The SERIOUS-PE study of RIETE participants and US Medicare beneficiaries

老年人肺栓塞治疗策略的性别差异: RIETE参与者和美国医疗保险受益人的严重PE研究

2024-11-260
PRE
Polygenic Risk in Heart Failure - Evaluating the Ability of a Polygenic Risk Score to Identify Risk of Future Heart Failure Events in 60,000 Patients from 6 TIMI Randomized Trials

多基因风险与心力衰竭——评估多基因风险评分在识别6项TIMI随机试验中60,000名患者未来心力衰竭事件风险方面的能力

2024-11-120
PRE